cbdMD Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 109/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.00.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
cbdMD Inc's Score
Industry at a Glance
Industry Ranking
109 / 158
Overall Ranking
308 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.000
Target Price
+213.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
cbdMD Inc Highlights
StrengthsRisks
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 19.19M.
Undervalued
The company’s latest PE is -1.39, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 502.25K shares, increasing 27.27% quarter-over-quarter.
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
Ticker SymbolYCBD
CompanycbdMD Inc
CEOKennedy (T. Ronan)
Websitehttps://www.cbdmd.com/
FAQs
What is the current price of cbdMD Inc (YCBD)?
The current price of cbdMD Inc (YCBD) is 1.490.
What is the symbol of cbdMD Inc?
The ticker symbol of cbdMD Inc is YCBD.
What is the 52-week high of cbdMD Inc?
The 52-week high of cbdMD Inc is 6.538.
What is the 52-week low of cbdMD Inc?
The 52-week low of cbdMD Inc is 0.470.
What is the market capitalization of cbdMD Inc?
The market capitalization of cbdMD Inc is 13.27M.
What is the net income of cbdMD Inc?
The net income of cbdMD Inc is -7.70M.
Is cbdMD Inc (YCBD) currently rated as Buy, Hold, or Sell?
According to analysts, cbdMD Inc (YCBD) has an overall rating of Buy, with a price target of 2.000.
What is the Earnings Per Share (EPS TTM) of cbdMD Inc (YCBD)?
The Earnings Per Share (EPS TTM) of cbdMD Inc (YCBD) is -1.138.